Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (261-270 of 394) with videos related to

Pageof 40
Sort By:
Dermatology and Therapy|July 15, 2024
The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic DermatitisJennifer Soung, Vivian Laquer, Joseph F Merola, et al.
Dermatology (Basel, Switzerland)|January 29, 2020
Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM)Heather Kornmehl, Kristina Callis Duffin, Nicole Salame, et al.
Journal of the American Academy of Dermatology|January 1, 2026
Clarifying Psoriasis Disease Severity: A Position Statement from the National Psoriasis Foundation Medical BoardAndrew Blauvelt, Ronald Prussick, Joseph F Merola, et al.
Dermatology and Therapy|December 11, 2025
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 YearDiamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, et al.
The Journal of Rheumatology|August 15, 2023
Screening and Referral Strategies for the Early Recognition of Psoriatic Arthritis Among Patients With Psoriasis: Results of a GRAPPA SurveyKaiyang Song, Louisa Webb, Lihi Eder, et al.
American Journal of Clinical Dermatology|January 18, 2020
Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) InitiativeLourdes M Perez-Chada, Nicole F Salame, Adam R Ford, et al.
Dermatology and Therapy|February 10, 2024
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
Dermatology and Therapy|February 7, 2025
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis TrialsJoseph F Merola, Laura K Ferris, Jeffrey M Sobell, et al.
The Journal of Clinical and Aesthetic Dermatology|October 24, 2024
Diagnostic Delay of Psoriatic Arthritis of More Than Six Months Contributes to Poor Patient-Reported Outcome Measures in Depression, Social Ability, and Disease Impact: A Cross-sectional StudyMelissa P Zundell, Lourdes Perez-Chada, Neel Tapryal, et al.
The Journal of Rheumatology|December 1, 2025
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With GuselkumabWilliam Tillett, Laura C Coates, Marijn Vis, et al.
Pageof 40

Showing results (261-270 of 394) with videos related to

Sort By:
Pageof 40
Dermatology and Therapy|July 15, 2024
The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic DermatitisJennifer Soung, Vivian Laquer, Joseph F Merola, et al.
Dermatology (Basel, Switzerland)|January 29, 2020
Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM)Heather Kornmehl, Kristina Callis Duffin, Nicole Salame, et al.
Journal of the American Academy of Dermatology|January 1, 2026
Clarifying Psoriasis Disease Severity: A Position Statement from the National Psoriasis Foundation Medical BoardAndrew Blauvelt, Ronald Prussick, Joseph F Merola, et al.
Dermatology and Therapy|December 11, 2025
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 YearDiamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, et al.
The Journal of Rheumatology|August 15, 2023
Screening and Referral Strategies for the Early Recognition of Psoriatic Arthritis Among Patients With Psoriasis: Results of a GRAPPA SurveyKaiyang Song, Louisa Webb, Lihi Eder, et al.
American Journal of Clinical Dermatology|January 18, 2020
Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) InitiativeLourdes M Perez-Chada, Nicole F Salame, Adam R Ford, et al.
Dermatology and Therapy|February 10, 2024
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.
Dermatology and Therapy|February 7, 2025
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis TrialsJoseph F Merola, Laura K Ferris, Jeffrey M Sobell, et al.
The Journal of Clinical and Aesthetic Dermatology|October 24, 2024
Diagnostic Delay of Psoriatic Arthritis of More Than Six Months Contributes to Poor Patient-Reported Outcome Measures in Depression, Social Ability, and Disease Impact: A Cross-sectional StudyMelissa P Zundell, Lourdes Perez-Chada, Neel Tapryal, et al.
The Journal of Rheumatology|December 1, 2025
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With GuselkumabWilliam Tillett, Laura C Coates, Marijn Vis, et al.
Pageof 40